
Opinion|Videos|March 3, 2025
The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars
Panelists discuss how stakeholders can enhance biosimilar uptake through coordinated efforts in financial alignment, patient-centric pricing, professional education, simplified administrative processes, and collaborative data exchange.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How can different stakeholders such as providers, health systems, insurance providers, and pharmacy benefit managers work together more efficiently to optimize the uptake of biosimilars?
Advertisement
Related to this article

This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
2
Defining High-Efficacy MS Therapy: Access, Formularies, and Patient Choice
3
Health Equity & Access Weekly Roundup: November 20, 2026
4
Low CRC Incidence Found After Endoscopic Mucosal Resection
5




